Comprehensive Clinical Development Finalizes Acquisition of Charles River Clinical Services
Comprehensive Clinical Development, formerly operating as Comprehensive NeuroScience, Inc., announced today the acquisition of Charles River Clinical Services Northwest, Inc., including its 250-bed, 77,000-square-foot, Phase I-IIa facility located in Tacoma, Washington.
The increased capacity and capabilities deliver numerous benefits to support clients’ complete drug development programs, including:
- Geographic diversification allowing clients a more proximal location to conduct studies and increase service offerings from coast to coast
- Established experience in conducting radiolabeled studies
- Streamlined optimization and extensive expertise in biologics studies
- Access to leading physicians in numerous specialties including oncology, expansive patient populations and unique nuclear pharmacy capabilities, allowing for highly differentiated studies
- Specialized pharmacy services optimized for compounding, including radiolabeled compounds
- Extensive access to populations for targeting treatments for patients with Hepatitis C
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
